Trials / Completed
CompletedNCT01277406
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 4SC-201(Resminostat) | oral administration |
| DRUG | FOLFIRI | i.v. administration |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-02-01
- Completion
- 2015-02-01
- First posted
- 2011-01-14
- Last updated
- 2015-04-01
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01277406. Inclusion in this directory is not an endorsement.